BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11051256)

  • 1. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
    Mitsudomi T; Hamajima N; Ogawa M; Takahashi T
    Clin Cancer Res; 2000 Oct; 6(10):4055-63. PubMed ID: 11051256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications].
    Mitsudomi T; Takahashi T
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():345-52. PubMed ID: 9369906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
    Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
    Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
    Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
    Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of p53 alteration and myc family gene overexpression with the clinical characteristics of lung cancer.
    Bai L; Sun Y; Li S
    Chin Med J (Engl); 1997 Apr; 110(4):250-4. PubMed ID: 9594222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study].
    Wang XL; Zhang CM; Shi LY; Yu HP; Xu SQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep; 25(9):769-74. PubMed ID: 15555357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of the Rb expression in adenocarcinoma of the lung.
    Sugio K; Tsukamoto S; Ushijima C; Yamazaki K; Kase S; Yamaguchi M; Ondo K; Yano T; Sugimachi K
    Anticancer Res; 2001; 21(3B):1931-5. PubMed ID: 11497280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
    Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
    Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
    Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
    Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
    Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
    Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.